One in three of us will get cancer and increases in life expectancy indices will exacerbate this statistic in the future. Most current treatment options are poorly effective and have devastating side effects including hair loss, nausea, weakened immunity and fatigue to name but a few. However, advances in genomics, epigenomics and proteomics are informing a new era of milder and more effective treatments. This includes targeted therapies, immunotherapies, nanomedicines and patient biomarker stratification strategies making this the most exciting era to be working in cancer drug development.
BioMoti exists to transform the treatment of cancer patients by doing things differently. Oncojans™ are a new class of immunotherapeutic drug-loaded particles that target and gain entry to the tumour vasculature and cancer cells. They do this by taking advantage of the CD95L surface ligand that is selectively and heavily expressed in tumour vasculature and cancer cells but not healthy tissue. CD95L promotes tumour immune evasion, cancer cell proliferation and metastasis. It is an essential gene for cancer survival and promotes cancer stem cells. High levels of CD95L expression in patient tumours are associated with increased malignancy and poor prognosis. Once inside CD95L+ve tumour cells, Oncojans™ slowly release therapeutic drugs at the point of need whilst sparing healthy tissue. The oncojan™ platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals.
BMT101 is BioMoti’s showcase lead Oncojan™ based ovarian cancer candidate that has shown very promising potential in early preclinical studies; low toxicity and very high efficacy. BMT101 is very likely to be active in a greater number of CD95L+ve tumour types and BioMoti is seeking to develop further API-Oncojan™ candidates in collaboration with established drug developers.
Oncojan™ edge: The platform uses CD95R modified drug-loaded particles that exploit new insights to neutralize an essential tumour immune evasion and proliferation mechanism whilst loading the interior of tumour cells with toxic drug reservoirs. Advantages compared to existing technologies such as nanoparticles or antibody-drug conjugates (ADCs) include:
The QMB Innovation Centre
42 New Road